BRTX — BioRestorative Therapies, Inc.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1505497 ·
Last close
$0.25
Market Cap
$6.36M
52W High
$0.33
52W Low
$0.16
ADV30
1,971,135
Next earnings
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 23,170 15,785 -3,385,733 -2,154,405 4,640,279 3,112,679 1,614,637
Dec 2025 19,600 17,964 -3,825,300 -3,207,636 4,079,635 1,511,188 3,722,891
Sep 2025 11,800 1,230 -3,709,011 -3,038,277 5,642,662 602,444 3,435,683
Jun 2025 303,300 294,571 -3,305,287 -2,656,263 8,516,559 1,555,251 3,671,235

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,788,963
Investing CF
$8,897,470
Financing CF
$2,854,791
CapEx
$-186,962
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.40
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-169,920,690
Inventory
Receivables
$15,500
ST Investments
$1,441,734
EBIT TTM
$-15,647,132
Pretax Income TTM
$-14,241,975
Interest Exp TTM
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$359,700
EBITDA
$-15,437,147
Free Cash Flow
$-6,200,023
Enterprise Value
$2,000,246
Total Cash
$2,952,922
Total Debt
$42,282
Shares Out
25,478,170
Trailing EPS
$-1.06
Book Value
$0.04
ROE
-320.5%
ROA
-119.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 359,700 -15,647,132 -14,241,975 4,079,635 3,722,891 -10,788,963
Dec 2024 401,000 -11,555,194 -8,979,381 12,279,799 3,748,406 -8,230,346
Dec 2023 145,800 -15,137,441 -10,417,704 12,611,720 2,607,345 -6,430,211
Dec 2022 119,800 -18,863,507 -13,222,296 16,434,691 6,144,352 -5,913,100

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.52

Peers — same industry

TickerNameMarket CapLastDaily %
ADVB Advanced Biomed Inc. $6.51M $3.98
HLYK HealthLynked Corp $6.91M $2.35
ACON Aclarion, Inc. $7.78M $3.16
LUDG LUDWIG ENTERPRISES, INC. $5.04M $0.03
BGLC BioNexus Gene Lab Corp $5.00M $2.07

News headlines (Yahoo Finance, 1h cache)

Sector Update: Healthcare Stocks Decline Tuesday Afternoon
2026-05-26 17:50 · Yahoo
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
2026-05-26 15:00 · Yahoo
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
2026-05-15 16:00 · Yahoo
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 23:40 · Yahoo
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
2026-05-13 15:00 · Yahoo
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
2026-05-11 22:05 · Yahoo
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 21:55 · Yahoo
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
2026-05-07 16:00 · Yahoo
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-06 12:25 · Yahoo
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
2026-04-30 14:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.